T-BAP Targeting the Polycomb Machinery in BAP1-related Pathologies
- Coordinator
- Istituto Europeo Di Oncologia SRL, Italy
- Runs
- 1 January 2024 to 30 June 2025
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101111993
What the project is doing
In the project's own words, from its summary on CORDIS.
BAP1-related mutations are common genetic lesions of several cancers and neurodevelopmental disorders (NDDs). BAP1 is a deubiquitinase that removes the repressive mono-ubiquitination at histone H2AK119 (H2Aub1) deposited by the Polycomb Repressive Complex 1 (PRC1) by associating with several regulatory subunits to form the Polycomb Repressive Deubiquitinase (PR-DUB) complex. BAP1 inactivating mutations represent a hallmark in Malignant Mesothelioma (MM) for which genetic models proved its oncogenic role.
Mutations further extend to several other cancers, also involving other essential PR-DUB regulatory subunits. This makes PR-DUB inactivation a major oncogenic event with ~40k new diagnosis each year between EU and US for which no precision therapeutic approaches exist. The work of my Dissect-PcG ERC project found that the major role of BAP1 is to counteract H2Aub1 diffusion across the entire chromatin. This preserves chromatin plasticity enhancing Polycomb-mediated control of transcriptional identity, which is decommissioned when BAP1 is inactivated and oncogenic H2Aub1 accumulates.
We also found that diffused H2Aub1 is controlled by a specific form of PRC1 - namely PRC1.3/5 - immediately suggesting a strategy to “correct” the effects of BAP1-related mutations. Indeed, we found that specific PRC1.3/5 loss restored normal H2Aub1 levels while compromising MM cells viability, demonstrating the therapeutic potential of targeting this non-essential arm of PRC1 repressive machinery. By building a multidisciplinary team, the T-BAP project aims to develop compounds that can target PRC1.3/5 in living cells.
We propose to use PRC1.3/5 structural data to identify specific binders that can function as warheads for the development of PROTAC degraders. This will generate a new class of molecules for the development of therapeutic strategies that can aid oncological patients with BAP1-related mutations, with a further potential application in specific NDD syndromes.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Istituto Europeo Di Oncologia SRL | Milano | Italy | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI